Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors

Neuroendocrine Tumors Clinical Trial

Official title:

Phase II Study of Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02455596
• Other study ID #: JH-NETs-001
• Status: Recruiting
• Phase: Phase 2
• First received: May 21, 2015
• Last updated: January 4, 2016
• Start date: May 2015
• Est. completion date: December 2016

Study information

• Verified date: October 2015
• Source: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
• Contact: Xu Jianming, M.D.
• Phone: +861051128358
• Email: jmxu2003[@]yahoo.com
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of recombinant anti-tumor and anti-virus protein for injection in treating patients with advanced neuroendocrine tumors who have failed standard treatment or are unable to receive standard treatment.

Description:

This is a Phase Ⅱ exploratory clinical study. The purpose of this study is to evaluate the efficacy and safety of recombinant anti-tumor and anti-virus protein for injection in treating patients with advanced neuroendocrine tumors who have failed standard treatment or are unable to receive standard treatment.

Recombinant anti-tumor and anti-virus protein for injection, 10μg,im,3 times for the first week, followed by 20μg for two weeks, and followed a maintenance dose of 30μg, the frequency of administration is three times per week. Treatment continued until the patient died or had unacceptable toxicity or had disease progression or required to discontinue the treatment. At the time of disease progression, if investigators believe patients can continue to benefit from the investigational product, patients may be provided with recombinant anti-tumor and anti-virus protein for injection,but only survival follow-up datas will be recorded.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: December 2016
• Est. primary completion date: October 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Have been fully aware of the study and voluntarily signed the informed consent.

• At least 18 years old.

• Have a confirmed histological or cytological diagnosis of low- or intermediate-grade advanced NETs (unresectable or metastatic), the pathology must meet one of the following criteria: (a) primary site of lung or thymus (carcinoid) with mitotic count of = 10/10 High Power Field [HPF]) (b) other primary site (including primary unknown) with mitotic count of = 20/10 High Power Field [HPF] and Ki67 index of = 20%,or with Ki67 index of > 20% and well-differentiated.

• Patients who have failed standard treatment or are unable to receive standard treatment, and have disease progression within the past 12 months;

• At least one measurable lesion according to the RECIST 1.1 criteria that has not been previously locally treated.

• ECOG performance status 0, 1 or 2.

• Minimum of 4 weeks since any local radiotherapy or surgery for the control of symptoms or severe complications(local radiotherapy for the control of bone metastases is not the limit),and adequately recovered from toxicities of any prior therapy).

• Life expectancy of at least 3 months.

Exclusion Criteria:

• Prior treatment with Recombinant Anti-tumor and Anti-virus Protein for Injection.

• Prior treatment with Interferon.

• Pregnancy or breast-feeding women or women who may be pregnant were positive drug test before administration.

• Patient of child-bearing potential(male or less than 1 year postmenopausal women) were reluctant to take contraceptive measures.

• Patient who were allergic to Interferon-a or who had interferon-a antibody.

• Have brain metastases or previous history of brain metastases or history of seizures.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoid Tumor
• Neuroendocrine Tumors

Intervention

Drug:
• Recombinant anti-tumor and anti-virus protein for injection (Novaferon)
Recombinant anti-tumor and anti-virus protein for injection, 10µg, im, 3 times for first week,followed by 20µg for two weeks, and followed a maintenance dose of 30µg, the frequency of administration is three times per week.

Locations

Country	Name	City	State
China	307 Hospital of PLA	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival (PFS)	PFS is defined as the length of time from random assignment to disease progression or to death resulting from any cause other than the progress.	1 year	No
Primary	Disease control rate(DCR)	DCR is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments.	1 year	No
Secondary	Overall response rate(ORR)	ORR is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as best overall response according to radiological assessments.	1 year	No
Secondary	Overall survival (OS)	OS is defined as the length of time from random assignment to death or to last contact	3 years	No
Secondary	Adverse Events(AEs)	AEs are evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events v4.0.	1 year	Yes